Neuroendocrine tumors are rare in head and neck region, while larynx is the most common site of presentation where they represent 0.5-1.0% of epithelial tumor, whereas only few cases of small cell neuroendocrine tumor of base of tongue has been reported so far. A 56-year old male presented with growth base of tongue. After through investigations the growth confirmed as a case of poorly differentiated high grade small cell neuroendocrine carcinoma and was clinically labeled as stage III (T3N0M0). The patient was treated with radiotherapy and combination chemotherapy. Presently the patient is having stable disease without any symptoms.
IntroductIon N euroendocrine tumors are well known clinicopathological entities that mainly occur in lungs. Extra pulmonary small cell neuroendocrine tumors represent about 2.5% (1) . The head and neck region is uncommon site for occurrence of NET. Larynx is the most common site of presentation where they represent 0.5-1.0% of epithelial tumor (2) . The base of tongue neuroendocrine carcinoma is extremely rare. Only infinitesimal number of cases has been reported so far in base of tongue. The appropriate treatment protocols and therapeutic regimens are not defined due to rarity of these tumors.
cAse report A 56-year old smoker male presented with complaints of pain during swallowing. There were no complaints of fever, cough, weight loss and appetite loss. Past 
treAtment summAry
The patient was initially given three weekly intravenous chemotherapy with vincristine, doxorubicin and cyclophosphamide (VAC) and after 3 courses there was partial response but patient developed grade II neutropenia.
Then patient was given External Beam Radical Radiotherapy (66Gy/33 fraction/6.3 weeks). The patient was having no evidence of disease after four months of follow-up but subsequently he developed recurrence in form of growth over base of tongue, 2x3cm in size. CECT revealed enhancing soft tissue growth over right side base of tongue ( In view of the poor response and hematological toxicity subsequent to VAC regimen, patient was switched over to three weekly intravenous chemotherapy with carboplatin and Etoposide. Patient again developed grade II neutropenia and in view of the same, injectable etoposide was replaced by oral etoposide. Even with oral etoposide, patient developed grade II neutropenia but local disease was non progressive during this phase except few small lymph nodes, which were seen in right cervical region on CECT.
Due to hematological toxicity and the appearance of lymph nodes, the patient was switched to single agent weekly Paclitaxel. Presently the patient is having non progression of disease till now.
dIscussIon Neuroendocrine tumors are heterogeneous family of neoplasms with differences in histomorphology, tissue origin, clinical behavior and therapeutics implications. They are known to be clinically aggressive with early dissemination to neighboring organs and lymph nodes, and largely resistant to therapy.
The diagnosis of NET has remained a histological one: therefore the detailed pathologic examination and immunohistochemistry is necessary for establishment of diagnosis. The appropriate treatment protocols and therapeutic regimens are not defined due to rarity of these tumors. However, therapeutic modalities indicated for poorly differentiated NEC include surgery, combination chemotherapy and radiotherapy.
In present case the patient was first given Combination chemotherapy with VAC regimens and experienced partial response with grade II neutropenia. Patient remained disease free after radical radiotherapy for only four months. 
